Cargando…

Prevalence, risk factors, and prognosis of central nervous system manifestations in antiphospholipid syndrome

The central nervous system (CNS) is considered as one of the most frequently affected organs in antiphospholipid syndrome (APS). This study investigated the prevalence of CNS manifestations in APS and associated risk factors and evaluated stroke recurrence. We carried out this retrospective study fr...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Meige, Li, Gongming, Song, Xiaodong, Fan, Yangyi, Li, Chun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10235119/
https://www.ncbi.nlm.nih.gov/pubmed/37264095
http://dx.doi.org/10.1038/s41598-023-35955-2
_version_ 1785052639937953792
author Liu, Meige
Li, Gongming
Song, Xiaodong
Fan, Yangyi
Li, Chun
author_facet Liu, Meige
Li, Gongming
Song, Xiaodong
Fan, Yangyi
Li, Chun
author_sort Liu, Meige
collection PubMed
description The central nervous system (CNS) is considered as one of the most frequently affected organs in antiphospholipid syndrome (APS). This study investigated the prevalence of CNS manifestations in APS and associated risk factors and evaluated stroke recurrence. We carried out this retrospective study from 2009 to 2021 at Peking University People’s Hospital, which enrolled 342 APS patients, and 174 neurologic events were suffered by 119 patients (34.8%). Patients with and without CNS involvement were compared regarding demographics and laboratory parameters. The analysis showed that older age, livedo reticularis, and dyslipidaemia were significant related factors for CNS manifestations (P = 0.047, 0.038, and 0.030 respectively). The use of anticoagulants (P = 0.004), and/or hydroxychloroquine (P = 0.016) appeared to associated with a lower incidence of CNS manifestations. During a median follow-up of 4.1 years, 10 individuals developed new episodes of stroke in APS patients with previous ischemic strokes. Livedo reticularis, smoking and male gender may predict the risk of recurrent stroke (P = 0.020, 0.006, and 0.026 respectively). Collectively, our results indicated the protective and risk factors for CNS manifestations, as well as demonstrated that APS patients appeared at high risk of stroke recurrence despite current therapy.
format Online
Article
Text
id pubmed-10235119
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-102351192023-06-03 Prevalence, risk factors, and prognosis of central nervous system manifestations in antiphospholipid syndrome Liu, Meige Li, Gongming Song, Xiaodong Fan, Yangyi Li, Chun Sci Rep Article The central nervous system (CNS) is considered as one of the most frequently affected organs in antiphospholipid syndrome (APS). This study investigated the prevalence of CNS manifestations in APS and associated risk factors and evaluated stroke recurrence. We carried out this retrospective study from 2009 to 2021 at Peking University People’s Hospital, which enrolled 342 APS patients, and 174 neurologic events were suffered by 119 patients (34.8%). Patients with and without CNS involvement were compared regarding demographics and laboratory parameters. The analysis showed that older age, livedo reticularis, and dyslipidaemia were significant related factors for CNS manifestations (P = 0.047, 0.038, and 0.030 respectively). The use of anticoagulants (P = 0.004), and/or hydroxychloroquine (P = 0.016) appeared to associated with a lower incidence of CNS manifestations. During a median follow-up of 4.1 years, 10 individuals developed new episodes of stroke in APS patients with previous ischemic strokes. Livedo reticularis, smoking and male gender may predict the risk of recurrent stroke (P = 0.020, 0.006, and 0.026 respectively). Collectively, our results indicated the protective and risk factors for CNS manifestations, as well as demonstrated that APS patients appeared at high risk of stroke recurrence despite current therapy. Nature Publishing Group UK 2023-06-01 /pmc/articles/PMC10235119/ /pubmed/37264095 http://dx.doi.org/10.1038/s41598-023-35955-2 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Liu, Meige
Li, Gongming
Song, Xiaodong
Fan, Yangyi
Li, Chun
Prevalence, risk factors, and prognosis of central nervous system manifestations in antiphospholipid syndrome
title Prevalence, risk factors, and prognosis of central nervous system manifestations in antiphospholipid syndrome
title_full Prevalence, risk factors, and prognosis of central nervous system manifestations in antiphospholipid syndrome
title_fullStr Prevalence, risk factors, and prognosis of central nervous system manifestations in antiphospholipid syndrome
title_full_unstemmed Prevalence, risk factors, and prognosis of central nervous system manifestations in antiphospholipid syndrome
title_short Prevalence, risk factors, and prognosis of central nervous system manifestations in antiphospholipid syndrome
title_sort prevalence, risk factors, and prognosis of central nervous system manifestations in antiphospholipid syndrome
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10235119/
https://www.ncbi.nlm.nih.gov/pubmed/37264095
http://dx.doi.org/10.1038/s41598-023-35955-2
work_keys_str_mv AT liumeige prevalenceriskfactorsandprognosisofcentralnervoussystemmanifestationsinantiphospholipidsyndrome
AT ligongming prevalenceriskfactorsandprognosisofcentralnervoussystemmanifestationsinantiphospholipidsyndrome
AT songxiaodong prevalenceriskfactorsandprognosisofcentralnervoussystemmanifestationsinantiphospholipidsyndrome
AT fanyangyi prevalenceriskfactorsandprognosisofcentralnervoussystemmanifestationsinantiphospholipidsyndrome
AT lichun prevalenceriskfactorsandprognosisofcentralnervoussystemmanifestationsinantiphospholipidsyndrome